Gilead withdraws bladder cancer drug in US after failed trial

Gilead Sciences (GILD.O) said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a confirmatory trial.